Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

A new RAND report shows nearly 12% of U.S. adults now use GLP-1 drugs like Ozempic and Wegovy, and it’s changing how they shop. Food companies say the biggest shift isn’t in portion sizes but in the ...

Learn how GLP-1 medications support weight loss and heart health in perimenopause and postmenopause, plus get tips for ...

The impact of popular U. S. weight-loss drugs like Ozempic and Wegovy (GLP-1 receptor agonists), upon their initial ...

GLP-1 weight-loss drugs have already seen massive success in the US. While they've made some headway into the European market ...

GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity or overweight with a related health condition. Read on for everything you need to know about GLP-1s for weight loss, ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks and ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide and liraglutide mimic endogenous incretin signals to stimulate glucose-dependent insulin release, thereby suppressing glucagon, ...

Brooke Boyarsky Pratt, CEO, and Dr. Angela Fitch, chief medical officer, are both co-founders of knownwell. More than 12% of U.S. adults now take a GLP-1 medication, marking one of the ...

Direct Meds Reviews Prescription Access Pathways As New GLP-1 Formats Expand. LegitScript-certified telehealth platform ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety ...

GLP-1s for weight loss may not affect the risk of obesity-related cancers either way, an analysis of the existing evidence suggests.